{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:42:42Z","timestamp":1791492162366,"version":"4.3.4"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.kisu.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:13:49Z","timestamp":1784538829000},"page":"37-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The expanding role of biomarkers in the management of IgA nephropathy"],"prefix":"10.1016","volume":"15","author":[{"given":"Koyal","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-2811","authenticated-orcid":false,"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2026.01.004_bib1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1523-1755.2003.00840.x","article-title":"Pathophysiology of proteinuria","volume":"63","author":"D'Amico","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.semnephrol.2004.01.001","article-title":"Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome","volume":"24","author":"D'Amico","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ki.2012.160","article-title":"In search of a better understanding of IgA nephropathy-associated hematuria","volume":"82","author":"Eitner","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41467-023-36173-0","article-title":"Next-generation morphometry for pathomics\u2014data mining in histopathology","volume":"14","author":"Holscher","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kisu.2026.01.004_bib6","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1093\/ndt\/gfy130","article-title":"Omics studies for comprehensive understanding of immunoglobulin A nephropathy: state-of-the-art and future directions","volume":"33","author":"Schena","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.004_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108525","article-title":"Single-cell transcriptomics reveal immune mechanisms of the onset and progression of IgA nephropathy","volume":"33","author":"Zheng","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645988","article-title":"A partial picture of the single-cell transcriptomics of human IgA nephropathy","volume":"12","author":"Tang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2026.01.004_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12920-023-01494-y","article-title":"Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on bioinformatics analysis","volume":"16","author":"Li","year":"2023","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.kisu.2026.01.004_bib11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.572754","article-title":"Monitoring immune responses in IgA nephropathy: biomarkers to guide management","volume":"11","author":"Selvaskandan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib14","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.004_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1016\/j.kisu.2026.01.004_bib17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","article-title":"Regression of IgA nephropathy: a repeat biopsy study","volume":"39","author":"Hotta","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.004_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","article-title":"Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation","volume":"28","author":"Shen","year":"2015","journal-title":"J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","article-title":"Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis","volume":"68","author":"Inker","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.004_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib22","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib23","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.004_bib24","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"issue":"4S","key":"10.1016\/j.kisu.2026.01.004_bib25","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib27","author":"Calliditas Therapeutics"},{"key":"10.1016\/j.kisu.2026.01.004_bib30","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1016\/j.ekir.2022.09.017","article-title":"One-year estimated GFR slope independently predicts clinical benefit in immunoglobulin A nephropathy","volume":"7","author":"Lafayette","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1053\/j.ajkd.2012.04.010","article-title":"Day-to-day variability in spot urine protein-creatinine ratio measurements","volume":"60","author":"Naresh","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2026.01.004_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.kisu.2026.01.002","article-title":"Management of IgA nephropathy and the expanding role of immunomodulation","volume":"15","author":"Canetta","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.004_bib33","doi-asserted-by":"crossref","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.01.004_bib34","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1681\/ASN.2017060639","article-title":"Persistent microscopic hematuria as a risk factor for progression of IgA nephropathy: new floodlight on a nearly forgotten biomarker","volume":"28","author":"Coppo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ndt\/12.3.418","article-title":"Survey of the Italian Registry of Renal Biopsies: frequency of the renal diseases for 7 consecutive years: the Italian Group of Renal Immunopathology","volume":"12","author":"Schena","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.004_bib36","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1515\/cclm-2021-0287","article-title":"Evaluation of red blood cell parameters provided by the UF-5000 urine auto-analyzer in patients with glomerulonephritis","volume":"59","author":"Mizuno","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.kisu.2026.01.003","article-title":"IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis","volume":"15","author":"Cheung","year":"2026","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2026.01.004_bib38","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ekir.2020.08.009","article-title":"Why target the gut to treat IgA nephropathy?","volume":"5","author":"Barratt","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/iji.12561","article-title":"Immunological drivers of IgA nephropathy: exploring the mucosa-kidney link","volume":"49","author":"Selvaskandan","year":"2022","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.kisu.2026.01.004_bib40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/0886022X.2018.1532907","article-title":"The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China","volume":"40","author":"Fan","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.kisu.2026.01.004_bib43","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/jcm13010123","article-title":"An update on the genetics of IgA nephropathy","volume":"13","author":"Xu","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib45","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1172\/JCI74475","article-title":"The genetics and immunobiology of IgA nephropathy","volume":"124","author":"Kiryluk","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.004_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.07260713","article-title":"Glomerular diseases: emerging tests and therapies for IgA nephropathy","volume":"9","author":"Canetta","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib47","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib48","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1681\/ASN.2006060658","article-title":"O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kisu.2026.01.004_bib50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1080\/1744666X.2023.2206119","article-title":"Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy","volume":"19","author":"Barratt","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/ki.2012.197","article-title":"The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression","volume":"82","author":"Zhao","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206865","article-title":"Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy","volume":"13","author":"Wada","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.004_bib53","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.2215\/CJN.11571210","article-title":"Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy","volume":"6","author":"Camilla","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098081","article-title":"A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases","volume":"9","author":"Yanagawa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.004_bib55","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1681\/ASN.2007091052","article-title":"Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy","volume":"19","author":"Gharavi","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12882-023-03198-y","article-title":"Serum levels of galactose-deficient IgA are elevated in patients with IgA nephropathy but do not correlate to disease activity or progression","volume":"24","author":"Eliasdottir","year":"2023","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1209394","article-title":"Diagnostic and prognostic value of galactose-deficient IgA1 in patients with IgA nephropathy: an updated systematic review with meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.0000000541","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","volume":"36","author":"Barratt","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib59","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2026.01.004_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib61","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib62","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ekir.2023.02.169","article-title":"Interim biomarker analysis from a randomized, double-blind, placebo-controlled, phase 2 trial of sibeprenlimab (VIS649) in participants with immunoglobulin A nephropathy","volume":"8","author":"Chan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000538242","article-title":"Indirect markers of intestinal damage in IgA nephropathy","volume":"148","author":"Pohjonen","year":"2024","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2026.01.004_bib64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/ckj\/sfac214","article-title":"Zonulin, as a marker of intestinal permeability, is elevated in IgA nephropathy and IgA vasculitis with nephritis","volume":"16","author":"Li","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.01.004_bib65","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","article-title":"The gut\u2013renal connection in IgA nephropathy","volume":"38","author":"Coppo","year":"2018","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.kisu.2026.01.004_bib67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jaut.2018.10.016","article-title":"The role of APRIL \u2013 a proliferation inducing ligand \u2013 in autoimmune diseases and expectations from its targeting","volume":"95","author":"Baert","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.kisu.2026.01.004_bib68","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-receptor in B cell selection and survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib69","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib70","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib71","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","article-title":"TLR9 and BAFF: their expression in patients with IgA nephropathy","volume":"10","author":"Li","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib72","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kisu.2026.01.004_bib73","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1681\/ASN.2015060677","article-title":"The role of TNF superfamily member 13 in the progression of IgA nephropathy","volume":"27","author":"Han","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib74","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib75","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/jcm10091987","article-title":"Serum levels of miR-148b and Let-7b at diagnosis may have important impact in the response to treatment and long-term outcome in IgA nephropathy","volume":"10","author":"Kouri","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib76","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1681\/ASN.2011060567","article-title":"Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy","volume":"23","author":"Serino","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/srep27209","article-title":"miR-21-5p renal expression is associated with fibrosis and renal survival in patients with IgA nephropathy","volume":"6","author":"Hennino","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib78","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1016\/j.febslet.2015.10.033","article-title":"Increased miR-374b promotes cell proliferation and the production of aberrant glycosylated IgA1 in B cells of IgA nephropathy","volume":"589","author":"Hu","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kisu.2026.01.004_bib79","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190967","article-title":"Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy","volume":"13","author":"Placzek","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.004_bib81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN111352","article-title":"Analysis of IgG subclass staining for IgG immunofluorescence-positive IgA nephropathy","volume":"102","author":"Oguchi","year":"2024","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib82","doi-asserted-by":"crossref","first-page":"781","DOI":"10.21037\/atm-20-7007","article-title":"Low serum IgG4 level: a potential diagnostic biomarker for IgA nephropathy","volume":"9","author":"Tian","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib83","article-title":"Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression","volume":"14","author":"Maixnerova","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.004_bib84","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1681\/ASN.2016060670","article-title":"Prognostic value of serum biomarkers of autoimmunity for recurrence of IgA nephropathy after kidney transplantation","volume":"28","author":"Berthoux","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib85","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s10157-013-0921-6","article-title":"Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy","volume":"18","author":"Suzuki","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib86","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1084\/jem.194.4.417","article-title":"Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy","volume":"194","author":"Moura","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib87","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1681\/ASN.2004111006","article-title":"Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy","volume":"16","author":"Moura","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trsl.2020.10.007","article-title":"CD71 mesangial IgA1 receptor and the progression of IgA nephropathy","volume":"230","author":"Jhee","year":"2021","journal-title":"Transl Res"},{"key":"10.1016\/j.kisu.2026.01.004_bib89","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/cei.12461","article-title":"Combined C4d and CD3 immunostaining predicts immunoglobulin (Ig)A nephropathy progression","volume":"179","author":"Faria","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib90","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1159\/000502579","article-title":"Clinical significance of galactose-deficient IgA1 by KM55 in patients with IgA nephropathy","volume":"44","author":"Zhang","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kisu.2026.01.004_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.638309","article-title":"Alternative complement pathway is activated and associated with galactose-deficient IgA(1) antibody in IgA nephropathy patients","volume":"12","author":"Chiu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib92","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1681\/ASN.2006040388","article-title":"Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy","volume":"17","author":"Oortwijn","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib93","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1681\/ASN.2005090923","article-title":"Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease","volume":"17","author":"Roos","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib94","article-title":"Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2026.01.004_bib95","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib96","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00467-017-3610-y","article-title":"Mesangial C4d deposition may predict progression of kidney disease in pediatric patients with IgA nephropathy","volume":"32","author":"Fabiano","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib97","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ekir.2017.11.015","article-title":"Progressive IgA nephropathy is associated with low circulating mannan-binding lectin-associated serine protease-3 (MASP-3) and increased glomerular factor H-related protein-5 (FHR5) deposition","volume":"3","author":"Medjeral-Thomas","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib98","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib99","article-title":"The role of mononuclear phagocyte system in IgA nephropathy: pathogenesis and prognosis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib100","article-title":"The role of renal macrophage, AIM, and TGF-beta1 expression in renal fibrosis progression in IgAN patients","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib101","first-page":"9299","article-title":"Clinical-pathologic significance of CD163 positive macrophage in IgA nephropathy patients with crescents","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769802","article-title":"Urinary soluble CD163 levels predict IgA nephropathy remission status","volume":"12","author":"Gong","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.kisu.2026.01.004_bib103","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.ekir.2024.07.031","article-title":"Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy","volume":"9","author":"Li","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib104","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12882-024-03574-2","article-title":"Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy","volume":"25","author":"Yoon","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10157-012-0707-2","article-title":"KIM-1 expression predicts renal outcomes in IgA nephropathy","volume":"17","author":"Kwon","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib106","doi-asserted-by":"crossref","first-page":"F885","DOI":"10.1152\/ajprenal.00331.2013","article-title":"Kidney injury molecule-1 expression in IgA nephropathy and its correlation with hypoxia and tubulointerstitial inflammation","volume":"306","author":"Lin","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kisu.2026.01.004_bib107","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41390-023-02542-0","article-title":"Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy","volume":"94","author":"Zhou","year":"2023","journal-title":"Pediatr Res"},{"key":"10.1016\/j.kisu.2026.01.004_bib108","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/ndt\/gfab163","article-title":"Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis","volume":"37","author":"Sparding","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.004_bib109","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.3390\/biom13071093","article-title":"Unique biomarkers of collagen type III remodeling reflect different information regarding pathological kidney tissue alterations in patients with IgA nephropathy","volume":"13","author":"Sparding","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.kisu.2026.01.004_bib110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/ndt\/gfv301","article-title":"Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy","volume":"31","author":"Genovese","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2026.01.004_bib111","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12882-017-0482-0","article-title":"Urinary sediment miRNAs reflect tubulointerstitial damage and therapeutic response in IgA nephropathy","volume":"18","author":"Liang","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib112","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40364-024-00619-4","article-title":"Blood and urine biomarkers of disease progression in IgA nephropathy","volume":"12","author":"Duan","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.kisu.2026.01.004_bib113","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000343452","article-title":"Urinary miR-21, miR-29, and miR-93: novel biomarkers of fibrosis","volume":"36","author":"Wang","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib114","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2026.01.004_bib115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nep.13592","article-title":"Is immunoglobulin A nephropathy different in different ethnic populations?","volume":"24","author":"Yeo","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kisu.2026.01.004_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-007-0010-9","article-title":"Chronic kidney disease perspectives in Japan and the importance of urinalysis screening","volume":"12","author":"Yamagata","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.kisu.2026.01.004_bib117","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ekir.2020.07.012","article-title":"IgA nephropathy genetic risk score to estimate the prevalence of IgA nephropathy in UK Biobank","volume":"5","author":"Sukcharoen","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2026.01.004_bib118","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.kint.2022.02.042","article-title":"Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy","volume":"102","author":"Barbour","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib119","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.kisu.2026.01.004_bib120","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.kint.2020.12.028","article-title":"Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression","volume":"99","author":"Pawluczyk","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2026.01.004_bib121","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s12325-024-02793-1","article-title":"Development of a conceptual model for the patient experience of immunoglobulin A nephropathy (IgAN): a qualitative literature review","volume":"41","author":"Aldhouse","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.kisu.2026.01.004_bib122","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.ekir.2023.06.016","article-title":"Clinicopathological characteristics of adult IgA nephropathy in the United States","volume":"8","author":"Caster","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171626000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:06:07Z","timestamp":1785974767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171626000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2157171626000043"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.004","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The expanding role of biomarkers in the management of IgA nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2026.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2025.12.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}